Morningstar

Alligator to Present 24-Month OPTIMIZE-1 Data at ESMO GI 2025

LUND, SWEDEN / ACCESS Newswire / July 1, 2025 / Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immunotherapies, today announced that ...
ascopubs.org

Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer.

Delineation of immunotherapeutic predictive versus prognostic transcriptional programs to identify SLC22A5-centric carnitine metabolism-driven resistance to anti-PD-L1 treatment in advanced ...
Fox2Now St. Louis

Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg

LUND, Sweden, March 23, 2022 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the ongoing OPTIMIZE-1 clinical Phase Ib/II trial in first-line metastatic ...
WOOD-TV

Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society ...

OCS-01 positive results in the first Phase 3 OPTIMIZE-1 trial were presented at the American Society of Cataract and Refractive Surgery (ASCRS) while topline readout from the second Phase 3 OPTIMIZE-2 ...